NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman o ...

Waltham, Massachusetts, April 21, 2025 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension" or the "Company"), a leader in Digital Manufacturing solutions, today provided an update on Desktop Metal. Desktop Metal, a subsidiary of Nano Dimension, has commenced a process to explore all available strategic alternatives to address its liabilities and liquidity needs. Desktop Metal has appointed Robert Warshauer to its Board of Directors and engaged Piper Sandler & Co. and FTI Consulting, Inc. ...

Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan Urges Stockholders to Defend Board Independence from Majority Influence by Individual 2.8% Stockholder, Mangless, Who Had Three Nominees Elected to the Board in 2023 Mangless Has Not Detailed any Strategies, Plans, or New Ideas to Imp ...

Group 1 - Domino's Pizza is offering a 50% discount on all menu-priced pizzas ordered online from April 21-27, 2025 [1][2][3] - The promotion is aimed at enhancing customer engagement during the spring season, providing an opportunity for casual dining or gatherings [3] - Domino's offers a variety of crust options and specialty pizzas to cater to diverse customer preferences [3] Group 2 - Founded in 1960, Domino's Pizza is the largest pizza company globally, with over 21,300 stores in more than 90 markets [4] - In 2024, Domino's reported global retail sales exceeding $19.1 billion, with a significant portion of sales generated through digital channels [4] - Independent franchise owners operate 99% of Domino's stores, highlighting the company's franchise-based business model [4]

Core Insights - BioStem Technologies, Inc. is a leading MedTech company specializing in placental-derived products for advanced wound care [1][3] - The CEO, Jason Matuszewski, will present at the Centri Capital Conference on April 22, 2025, at Nasdaq headquarters in New York City [1] Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of allografts utilizing perinatal tissue [3] - The company employs a proprietary BioREtain processing method aimed at preserving growth factors and tissue structure [3] - BioStem's quality management system is accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3] - The product portfolio includes brands such as AmnioWrap™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at the FDA registered and AATB accredited facility in Pompano Beach, Florida [3]

Core Points - HBT Financial, Inc. reported a net income of $19.1 million, or $0.60 diluted earnings per share, for Q1 2025, a decrease from $20.3 million, or $0.64 per share in Q4 2024, but an increase from $15.3 million, or $0.48 per share in Q1 2024 [2][4][9] - The company expressed confidence in its performance for 2025 despite economic uncertainties, citing strong profitability and a solid balance sheet [3][4] - Adjusted net income for Q1 2025 was $19.3 million, or $0.61 per diluted share, slightly down from $19.5 million, or $0.62 per share in Q4 2024, and up from $18.1 million, or $0.57 per share in Q1 2024 [6][9] Financial Performance - Net interest income for Q1 2025 was $48.7 million, a 2.8% increase from $47.4 million in Q4 2024, and a 4.3% increase from $46.7 million in Q1 2024 [7][8] - The net interest margin for Q1 2025 was 4.12%, up from 3.96% in Q4 2024 and 3.94% in Q1 2024 [9][11] - Noninterest income decreased by 20.0% to $9.3 million in Q1 2025 from $11.6 million in Q4 2024, but increased by 65.4% from $5.6 million in Q1 2024 [13][14] Asset Quality - Nonperforming assets totaled $5.6 million, or 0.11% of total assets, down from $8.0 million, or 0.16% in Q4 2024, and $9.9 million, or 0.20% in Q1 2024 [21] - The company recorded net charge-offs of $0.4 million, or 0.05% of average loans on an annualized basis, compared to $0.7 million, or 0.08% in Q4 2024 [23] - The allowance for credit losses was 1.22% of total loans as of March 31, 2025, compared to 1.21% at the end of Q4 2024 [24] Capital Position - As of March 31, 2025, the company exceeded all regulatory capital requirements under Basel III, with a total capital to risk-weighted assets ratio of 16.85% [25] - Tangible book value per share increased by $0.63 to $15.43 as of March 31, 2025, reflecting a 4.3% increase for the quarter and a 17.0% increase year-over-year [4][25] - The company did not repurchase shares during Q1 2025, maintaining $15.0 million available under its stock repurchase program [26] Loan and Deposit Trends - Total loans outstanding were $3.46 billion at March 31, 2025, nearly unchanged from $3.47 billion at December 31, 2024, but up from $3.35 billion at March 31, 2024 [18] - Total deposits increased to $4.38 billion at March 31, 2025, from $4.32 billion at December 31, 2024, and $4.36 billion at March 31, 2024 [19]

Core Insights - Kraig Biocraft Laboratories, Inc. is advancing its recombinant spider silk production, currently in the largest batch to date [1] - The first half of the current production batch has been completed, with the second half expected to finish in the next 14 days [2] - This production run marks a significant milestone with the first simultaneous batches of BAM-1 produced in new facilities, demonstrating the scalability and reliability of the production model [3] Production Progress - The company has successfully completed the production of all BAM-1 hybrid eggs for release over the next month, ensuring a steady supply for future production cycles [4] - The execution of simultaneous production batches showcases the scalability of the technology from batch processing to continuous flow manufacturing [5] Strategic Positioning - The company is positioned to accelerate the growth and commercialization of its eco-friendly and high-performance spider silk fibers, with ongoing updates expected as production and commercialization goals progress [5] - Kraig Labs is recognized as a leading developer of genetically engineered spider silk-based fiber technologies, with significant implications for the global textile industry [7]

Core Viewpoint - Invivyd, Inc. has secured a $30 million term loan facility with Silicon Valley Bank to support its development pipeline, particularly focusing on the monoclonal antibody candidate VYD2311 for COVID-19 [1][2] Group 1: Financial Developments - The $30 million term loan facility allows for future capital drawdown contingent on meeting specific conditions and milestones [1] - The financing is non-dilutive, providing balance sheet flexibility for the company to concentrate on enhancing per-share value [2] Group 2: Product Development - VYD2311 is a novel monoclonal antibody candidate aimed at addressing the urgent need for new COVID-19 prophylactic and therapeutic options [2] - The candidate is designed to deliver clinically meaningful titer levels through a more patient-friendly intramuscular administration route [2] - VYD2311 utilizes Invivyd's proprietary technology platform and is optimized for neutralizing contemporary virus lineages [3] Group 3: Related Products - PEMGARDA (pemivibart) is another investigational monoclonal antibody developed from adintrevimab, showing in vitro neutralizing activity against major SARS-CoV-2 variants [4][5] - PEMGARDA has received emergency use authorization for pre-exposure prophylaxis in certain immunocompromised patients [5][6] - The product is not authorized for treatment or post-exposure prophylaxis of COVID-19 and should not replace vaccination [6][10] Group 4: Regulatory Context - The emergency use of PEMGARDA is authorized only during the COVID-19 pandemic under specific conditions, including variant susceptibility [10] - The company has received emergency use authorization from the U.S. FDA for a monoclonal antibody in its pipeline [11]

Core Insights - Arvinas, Inc. announced new preclinical combination data for ARV-393, which will be presented at the AACR Annual meeting, highlighting its potential to be combined with standard lymphoma treatments [1][2] Group 1: Product Information - ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a key driver of B-cell lymphomas [2][4] - The degradation of BCL6 through PROTAC technology aims to address the traditionally undruggable nature of this protein, which plays a significant role in B cell tolerance and proliferation [4] Group 2: Presentation Details - The presentation of ARV-393 will take place on April 28, 2025, at the AACR Annual meeting, with the poster titled "ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models" [3] - The session will focus on experimental and molecular therapeutics, specifically under the title "Degraders and Glues 2" [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize the body's natural protein disposal system to selectively degrade disease-causing proteins [5] - The company is advancing multiple investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5]

Core Viewpoint - BioCryst Pharmaceuticals will report its first quarter 2025 financial results on May 5, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases [3]. - The company utilizes structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases [3]. - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3].